Stereotactic radiosurgery for unresectable adenocarcinoma of the pancreas: Initial experience at Sinai Hospital of Baltimore

Christopher Hoffelt, Mukund Didolkar

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Adenocarcinoma of the pancreas remains among the most lethal cancers in the United States. For most of the past four decades, little has changed in the treatment and poor survival associated with this tumor [1]. Surgery is still the only treatment associated with cure, though most patients have unresectable disease at diagnosis. Even in favorable, resectable disease, median survival is only 15-24 months [2, 3], with 15-20% long-term survival. Aggressive chemo-radiotherapy trials have demonstrated only marginal improvements in overall survival, rarely with long-term survival.

Original languageEnglish (US)
Title of host publicationTreating Tumors that Move with Respiration
PublisherSpringer Berlin Heidelberg
Pages241-246
Number of pages6
ISBN (Print)9783540698852
DOIs
StatePublished - 2007

Fingerprint

Baltimore
Radiosurgery
Pancreas
Adenocarcinoma
Survival
Neoplasms
Radiotherapy
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hoffelt, C., & Didolkar, M. (2007). Stereotactic radiosurgery for unresectable adenocarcinoma of the pancreas: Initial experience at Sinai Hospital of Baltimore. In Treating Tumors that Move with Respiration (pp. 241-246). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-69886-9_24

Stereotactic radiosurgery for unresectable adenocarcinoma of the pancreas : Initial experience at Sinai Hospital of Baltimore. / Hoffelt, Christopher; Didolkar, Mukund.

Treating Tumors that Move with Respiration. Springer Berlin Heidelberg, 2007. p. 241-246.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hoffelt, C & Didolkar, M 2007, Stereotactic radiosurgery for unresectable adenocarcinoma of the pancreas: Initial experience at Sinai Hospital of Baltimore. in Treating Tumors that Move with Respiration. Springer Berlin Heidelberg, pp. 241-246. https://doi.org/10.1007/978-3-540-69886-9_24
Hoffelt C, Didolkar M. Stereotactic radiosurgery for unresectable adenocarcinoma of the pancreas: Initial experience at Sinai Hospital of Baltimore. In Treating Tumors that Move with Respiration. Springer Berlin Heidelberg. 2007. p. 241-246 https://doi.org/10.1007/978-3-540-69886-9_24
Hoffelt, Christopher ; Didolkar, Mukund. / Stereotactic radiosurgery for unresectable adenocarcinoma of the pancreas : Initial experience at Sinai Hospital of Baltimore. Treating Tumors that Move with Respiration. Springer Berlin Heidelberg, 2007. pp. 241-246
@inbook{b018789f86d1457b902ed6b3241524e4,
title = "Stereotactic radiosurgery for unresectable adenocarcinoma of the pancreas: Initial experience at Sinai Hospital of Baltimore",
abstract = "Adenocarcinoma of the pancreas remains among the most lethal cancers in the United States. For most of the past four decades, little has changed in the treatment and poor survival associated with this tumor [1]. Surgery is still the only treatment associated with cure, though most patients have unresectable disease at diagnosis. Even in favorable, resectable disease, median survival is only 15-24 months [2, 3], with 15-20{\%} long-term survival. Aggressive chemo-radiotherapy trials have demonstrated only marginal improvements in overall survival, rarely with long-term survival.",
author = "Christopher Hoffelt and Mukund Didolkar",
year = "2007",
doi = "10.1007/978-3-540-69886-9_24",
language = "English (US)",
isbn = "9783540698852",
pages = "241--246",
booktitle = "Treating Tumors that Move with Respiration",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Stereotactic radiosurgery for unresectable adenocarcinoma of the pancreas

T2 - Initial experience at Sinai Hospital of Baltimore

AU - Hoffelt, Christopher

AU - Didolkar, Mukund

PY - 2007

Y1 - 2007

N2 - Adenocarcinoma of the pancreas remains among the most lethal cancers in the United States. For most of the past four decades, little has changed in the treatment and poor survival associated with this tumor [1]. Surgery is still the only treatment associated with cure, though most patients have unresectable disease at diagnosis. Even in favorable, resectable disease, median survival is only 15-24 months [2, 3], with 15-20% long-term survival. Aggressive chemo-radiotherapy trials have demonstrated only marginal improvements in overall survival, rarely with long-term survival.

AB - Adenocarcinoma of the pancreas remains among the most lethal cancers in the United States. For most of the past four decades, little has changed in the treatment and poor survival associated with this tumor [1]. Surgery is still the only treatment associated with cure, though most patients have unresectable disease at diagnosis. Even in favorable, resectable disease, median survival is only 15-24 months [2, 3], with 15-20% long-term survival. Aggressive chemo-radiotherapy trials have demonstrated only marginal improvements in overall survival, rarely with long-term survival.

UR - http://www.scopus.com/inward/record.url?scp=84891403439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891403439&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-69886-9_24

DO - 10.1007/978-3-540-69886-9_24

M3 - Chapter

AN - SCOPUS:84891403439

SN - 9783540698852

SP - 241

EP - 246

BT - Treating Tumors that Move with Respiration

PB - Springer Berlin Heidelberg

ER -